Blogs
Welcome to Unibest's Blogs section! Here, you will find valuable insights and in-depth reports covering various topics related to drugs and diseases. Our blogs aim to provide an enhanced understanding of the clinical significance and breakthroughs your clients can make. Stay updated with the latest trends, technological advancements, and industry analyses as we dive deep into the world of pharmaceuticals, giving you the knowledge and resources you need to stay ahead of the competition.

Pomalidomide

If you want to know more about the Pomalidomide, the following articles will give you some help. These news is the latest market situation, trend in development, or related tips of the Pomalidomide industry. More news about Pomalidomide, are being released. Follow us / contact us for more Pomalidomide information!
  • Drug Patent & Exclusivity Expiration Report - Week of June 16 2025

    2025-06-16

    This week, there are 9 drugs in the patent and exclusivity list. They are: - BRISTOL MYERS SQUIBB CO's POMALYST, containing active ingredient POMALIDOMIDE - VIATRIS SPECIALTY LLC's TOBI PODHALER, containing active ingredient TOBRAMYCIN - RHYTHM PHARMACEUTICALS INC's IMCIVREE, containing active ingredient SETMELANOTIDE ACETATE - PF PRISM CV's BOSULIF, containing active ingredient BOSUTINIB MONOHYDRATE - JANSSEN PHARMACEUTICALS INC's XARELTO, containing active ingredient RIVAROXABAN - BPI LABS LLC's ABLYSINOL, containing active ingredient ALCOHOL - HORIZON THERAPEUTICS USA INC's PROCYSBI, containing active ingredient CYSTEAMINE BITARTRATE - NOVARTIS PHARMACEUTICALS CORP's TAFINLAR, containing active ingredient DABRAFENIB MESYLATE - NOVARTIS PHARMACEUTICALS CORP's MEKINIST, containing active ingredient TRAMETINIB DIMETHYL SULFOXIDE Read More